Pharma BD Deal Intelligence

Endo International plc / DAVA Pharmaceuticals, Inc.

2014 · Acquisition/Merger · $600M · Complete

Announcement Sentiment

Strongly positive

Endo agreed to acquire privately held generics maker DAVA Pharmaceuticals for $575M cash plus $25M sales-milestone earn-out. DAVA generated $131M revenue and ~$100M adj. EBITDA in 2013 across a niche specialty generics portfolio. Closed August 6, 2014.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Stalled

Assessment window: 5yr post-close.

Key facts

Announced Jun 24, 2014
Closed Aug 06, 2014
Deal value $600M
Deal type Acquisition/Merger
Therapeutic area Specialty generics
Indications Specialty generics
Key assets Specialty generics (women's health, oncology, transplant)
Mechanism N/A (generics portfolio)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals